Replies to post #181532 on Biotech Values

[genisi]

BIIB033 anti-LINGO-1 phase I data

No reason to be disappointed yet Ian, MS patients only got two doses of BIIB033 in the phase I trial. We should wait for data from the following phase II trials (first to report is the one in AON and much later the MS trial), to discuss efficacy.

http://clinicaltrials.gov/ct2/show/NCT01721161?term=NCT01721161&rank=1

http://clinicaltrials.gov/ct2/show/NCT01864148?term=NCT01864148&rank=1